GHK-Cu Removed From the FDA Category 2 Bulks List in 2026: Copper-Peptide Chemistry & Status

According to legal analyses of the FDA's April 15, 2026 action, GHK-Cu is no longer classified in Category 2 of the agency's bulk drug substances guidance for compounding. Reporting indicates the change took effect approximately April 22, 2026, about seven days after the notice. This is described as a withdrawal from the interim 'do not compound' category, not a market authorization.

An important nuance distinguishes GHK-Cu from the other peptides in the same announcement. According to Frier Levitt's analysis, the FDA treated GHK-Cu by route of administration: the injectable form was removed from Category 2, while the non-injectable form was separately removed from Category 1 (the 'under evaluation, no identified significant safety risk' bucket). Per that analysis, both routes left their respective interim categories in the same action. (Note: some summaries of the notice reference only the Category 1 change for GHK-Cu; the dual-route reading follows Frier Levitt.)

GHK-Cu was reported to be one of 12 peptides affected by the April 2026 decision. According to these analyses, the broader move followed the withdrawal of the underlying nominations that had originally placed these substances under FDA review for the Section 503A bulk drug substances list.

The FDA's category framework governs whether a bulk substance may be used in pharmacy compounding under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Category 1 covers substances under evaluation that have not been flagged for significant safety risks and that may be compounded pursuant to a valid prescription during review. Category 2 is described as reserved for substances the agency has determined raise significant safety concerns; these are not eligible for compounding unless the FDA issues an authorizing regulation.

According to the cited legal summaries, on April 15, 2026 the FDA announced it would remove 12 peptides from these interim categories, with removal effective on or about April 22, 2026. The agency is reported to have simultaneously scheduled two public Pharmacy Compounding Advisory Committee (PCAC) meetings — July 23–24, 2026, and a session before the end of February 2027 — to formally consider whether any of the substances should be added to the 503A bulks list.

Removal from Category 2 does not, by itself, place GHK-Cu on the 503A bulks list, and it is not an FDA approval of the substance for any use. According to legal analysis of the announcement, the affected peptides exist in a regulatory gray area until the PCAC meets and the FDA takes final action. The reported removal changes the interim classification; it does not resolve the substance's long-term compounding status.

Crucially for GHK-Cu specifically: according to Frier Levitt's analysis, it is not among the seven peptides slated for the July 23–24, 2026 PCAC review. Per that published schedule, the July meeting covers BPC-157, KPV, TB-500 (Thymosin Beta-4 fragment), MOTS-c, Emideltide (DSIP), Semax, and Epitalon. GHK-Cu, alongside Cathelicidin LL-37, Dihexa, PEG-MGF, and Melanotan II, is reported to be scheduled for the later session before the end of February 2027. On this reading, framing a 'July 2026' substantive change for GHK-Cu would conflate two timelines — the removal was reported for April 2026, while the PCAC review for GHK-Cu is reported for February 2027.

• Removal IS (per the cited analyses): a withdrawal of GHK-Cu from the interim Category 2 (injectable) and Category 1 (non-injectable) designations, effective ~April 22, 2026.
• Removal is NOT: FDA approval, a finding of safety or efficacy, or addition to the 503A bulks list.
• Still pending: PCAC review of GHK-Cu, reported to be scheduled for the meeting before the end of February 2027.
• Unchanged for researchers: GHK-Cu remains a research-use-only chemical with no human-use authorization tied to this regulatory action.

GHK-Cu is a coordination complex of a small endogenous tripeptide with a copper(II) ion. The peptide portion, GHK, is glycyl-L-histidyl-L-lysine — three amino acid residues in sequence: glycine (Gly), L-histidine (His), and L-lysine (Lys). Its INCI and common cosmetic-chemistry name is copper tripeptide-1. The free tripeptide has the molecular formula C14H24N6O4 and a molar mass of 340.38 g/mol; the assembled copper complex adds a chelated Cu(II) center.

The copper coordination is the defining structural feature. The Cu(II) ion is bound primarily through nitrogen donor atoms: the imidazole side-chain nitrogen of the histidine residue, the alpha-amino nitrogen of the N-terminal glycine, and the deprotonated amide nitrogen of the glycyl–histidyl peptide bond, with additional stabilization from a neighboring carboxylate oxygen in an approximately square-planar geometry. Histidine's imidazole ring is described in the literature as the high-affinity anchoring site for the copper center.

GHK occurs naturally in human plasma, saliva, and urine, where it functions as a copper-binding ligand. Reported plasma concentrations decline with age: literature values cited in the references give roughly 200 ng/mL at age 20 falling to about 80 ng/mL by age 60 — an approximately 60% decrease over four decades. This is presented strictly as a descriptive biochemical observation, not as a basis for any use claim.

From a coordination-chemistry standpoint, GHK's high reported affinity for Cu(II) lets it act as a copper-binding ligand. Studies of the GHK–Cu(II) system and its synthetic analogues characterize the stability and redox behavior of the complex, which is the property that distinguishes the copper-bound form (GHK-Cu) from the apo-peptide (GHK) in both research and analytical contexts.

For context, the April 2026 action is reported to have covered a defined set of 12 peptides. The table below lists them as named in the legal summaries of the announcement, with GHK-Cu shown by its dual route classification per Frier Levitt's analysis. The per-meeting PCAC assignments below follow that same analysis and should be confirmed against the FDA's primary schedule.

The regulatory change coincided with a sharp rise in public search attention. Trade and market commentary in 2026 describes GHK-Cu as among the fastest-growing peptide search terms of the year, with interest reported to be up more than 1,000% year-over-year and search traffic more than doubling over roughly the prior 18 months. These figures come from secondary trade commentary and are presented as reported search-volume trends, not verified market data.

For laboratory researchers, surging search interest raises a practical concern that is independent of the regulatory status: a wider gap between marketing claims and verifiable chemical identity. Heightened attention often correlates with more unverified products and inconsistent sourcing, which is precisely where independent certificate-of-analysis (COA) verification of purity, mass, and identity becomes relevant.

According to legal analyses of the April 2026 action, no. The injectable form of GHK-Cu was reported to be removed from Category 2 effective approximately April 22, 2026, and the non-injectable form removed from Category 1 in the same action. On that reading it is no longer in either interim category. These details should be confirmed against the FDA's primary notice.

No. Removal from Category 2 is not an approval and does not add GHK-Cu to the 503A bulks list. According to the cited analyses, the substance occupies a regulatory gray area pending PCAC review, and the FDA has made no finding of safety or efficacy through this action.

According to Frier Levitt's analysis, GHK-Cu is scheduled for the PCAC meeting before the end of February 2027, not the July 23–24, 2026 session. That same source places seven other peptides — including BPC-157, TB-500, and Semax — at the July meeting.

GHK-Cu is the tripeptide glycyl-L-histidyl-L-lysine (Gly-His-Lys, formula C14H24N6O4, molar mass 340.38 g/mol) coordinated to a copper(II) ion. Per the cited references, copper is anchored largely through the histidine imidazole nitrogen, the N-terminal amine nitrogen, and a deprotonated amide nitrogen.

According to Frier Levitt's analysis, the FDA classified the two routes separately under its interim framework: injectable GHK-Cu sat in Category 2, while non-injectable GHK-Cu sat in Category 1. The April 2026 action is reported to have removed each route from its respective category, which is why the same substance appears under two classifications in the announcement summaries.

• FDA Peptide Reclassification 2026: 14 Peptides Return to Category 1 -> /learn/fda-peptide-reclassification-2026-14-peptides-return-to-category-1
• Are Research Peptides Legal? -> /learn/are-research-peptides-legal
• Research-Use-Only (RUO) Legal Status for Peptides: Complete Guide -> /learn/research-use-only-ruo-legal-status-for-peptides-complete-guide
• Verify a Peptide Source (COA Check) -> /verify
• Compare Peptide Vendors and Prices -> /compare